Form 4: HealthEquity Director Stuart Parker's RSU Vesting

HealthEquity Director Stuart B. Parker reported the vesting of 1,263 restricted stock units, increasing his direct beneficial ownership.

Summary

• Stuart B. Parker, a Director of HealthEquity, Inc. (HQY), reported a transaction involving the acquisition of common stock.
• On February 2, 2026, 1,263 restricted stock units (RSUs) vested, representing a contingent right to receive one share of the issuer's common stock per unit.
• The transaction price for these acquired securities was $0.
• Following this transaction, Stuart B. Parker directly beneficially owns 23,098 shares of HealthEquity Common Stock.
• The vesting schedule for the remaining RSUs is as follows: 316 shares on May 1, 2026; 316 shares on August 1, 2026; and 315 shares on November 1, 2026.
• Vested shares will be delivered upon the earlier of a change of control, termination of service, or the reporting person's death, as defined in the issuer's 2024 equity incentive plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine, positive event demonstrating continued alignment of a director's interests with shareholders through equity compensation, without indicating any new operational or strategic developments.

Positives

• The vesting of restricted stock units increases Director Stuart B. Parker's direct beneficial ownership in HealthEquity, aligning his interests further with those of shareholders.
• The transaction is part of a pre-scheduled equity incentive plan, indicating a structured approach to executive compensation.

Future Outlook

The filing outlines a clear future vesting schedule for the remaining restricted stock units, with specific dates in May, August, and November 2026, indicating continued equity compensation for the director.

Industry Context

StockSavvy.ai notes that the vesting of restricted stock units is a standard component of executive and director compensation packages across various industries. This practice is designed to align the long-term interests of company leadership with those of shareholders by tying a portion of their compensation to the company's stock performance and continued service.

Comparison to Industry Standards

• Restricted stock unit (RSU) grants and vesting schedules are a common form of equity compensation for directors and executives in publicly traded companies, comparable to practices at peers in the healthcare technology and financial services sectors.
• The structure, where shares are delivered upon specific future events (change of control, termination, death), is typical for long-term incentive plans designed to promote retention and alignment.

Stakeholder Impact

• Shareholders: The increase in director's beneficial ownership through RSU vesting generally signals continued alignment of management's interests with shareholder value creation.

Next Steps

• 316 restricted stock units are scheduled to vest on May 1, 2026.
• 316 restricted stock units are scheduled to vest on August 1, 2026.
• The remaining 315 restricted stock units are scheduled to vest on November 1, 2026.
• Vested shares will be delivered to the reporting person upon the earlier of a change of control of the issuer, the reporting person's termination of service, or the reporting person's death.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled vesting of restricted stock units for a director. While it increases the director's beneficial ownership and aligns interests, it does not provide new material information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as it reflects a neutral impact on the stock's fundamental outlook based solely on this filing.

Keywords

HealthEquity, HQY, Stuart Parker, Form 4, SEC filing, restricted stock units, RSU, insider transaction, director ownership, equity compensation